Schizophrenia research and treatment

Schizophrenia is a severe psychiatric disorder characterized by hallucinations, delusions, and profound disruptions in thought, and researchers study it by tracing how genetic risk, early neurodevelopmental disruptions, and dopamine system dysfunction converge to produce its symptoms. While antipsychotic drugs remain the primary treatment and can reduce psychosis, they do little to address neurocognitive deficits or difficulties with social cognition, leaving many patients with lasting impairments in daily functioning. A central open question is how to identify and intervene during the prodromal phase—before full psychosis emerges—since earlier treatment likely improves long-term outcomes but requires better biomarkers to distinguish who will actually convert. Researchers are also working to understand why antipsychotic treatment so frequently leads to metabolic syndrome, and how cognitive therapies can be refined to complement medication and address the broader cognitive and social dimensions of the illness.

Works

143,659

Total citations

3,379,276

Keywords

Antipsychotic DrugsNeurocognitive DeficitsGenetic Association StudiesMetabolic SyndromeNeurodevelopmental ModelCognitive Therapy